Table 2 Long term regimen of Azithromycin and Tobramycin in stable phase of 37 children
From: Prognosis and treatment of 46 Chinese pediatric cystic fibrosis patients
Variables | N = 37 |
|---|---|
Azithromycin -no/total no (%) | 34/37 (91.89) |
Number of actual users | 31/34 (91.18) |
Duration -month | 25.69 ± 16.78 (0.5–62, median 23) |
Onset time -month | 3.77 ± 2.92 (1–12, median 3.0) |
Side effect -no/total no (%) | 3/34 (8.82) |
Tobramycin -no/total no (%) | 31/37 (83.78) |
Number of actual users -no/total no (%) | 29/31 (93.55) |
Duration -month | 24.60 ± 13.40 (0.5–48, median 24) |
Side effect -no/total no (%) | 0/31 (0.00) |